Monica Leslie

Monica Leslie

Auto-generated profile, based on publicly available information

Monica Leslie

Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), London, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2018 in European Eating Disorders Review
Verified
Journal Article
Closed access
PDF file
Janet TreasureJanet Treasure
Janet Treasure
MLMonica Leslie
Monica Leslie
RCRayane Chami
Rayane Chami
Fernando Fernández-ArandaFernando Fernández-Aranda
Fernando Fernández-Aranda

15 August 2018 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
MLMonica Leslie
Monica Leslie
PSPaulo Silva
Paulo Silva
YPYannis Paloyelis
Yannis Paloyelis
JBJames Blevins
James Blevins
JTJanet Treasure
Janet Treasure

10 July 2020 in European Eating Disorders Review
Verified
Journal Article
Open access
PDF file
KTKate Tchanturia
Kate Tchanturia
YDYasemin Dandil
Yasemin Dandil
ZLZhuo Li
Zhuo Li
KSKatherine Smith
Katherine Smith
MLMonica Leslie
Monica Leslie
SBSarah Byford
Sarah Byford
Objective: In the current economic context, it is critical to ensure that eating disorder (ED) treatments are both effective and cost‐effective. We describe the impact of a novel clinical pathway developed to better meet the needs of autistic patients with EDs on the length and cost of hospital admissions.Method: The pathway was based on the Institute for Healthcare's Model of Improvement methodology, using an iterative Plan, Do, Study, Act format to introduce change and to co‐produce the work with people with lived experience and with healthcare professionals. We explored the change in length and cost of admissions before and after the pathway was introduced.Results: Preliminary results suggest that the treatment innovations associated with this pathway have led to reduced lengths of admission for patients with the comorbidity, which were not seen for patients without the comorbidity. Estimated cost‐savings were approximately £22,837 per patient and approximately £275,000 per year for the service as a whole.Conclusion: Going forward, our aim is to continue to evaluate the effectiveness and cost‐effectiveness of investment in the pathway to determine whether the pathway improves the quality of care for patients with a comorbid ED and autism and is good value for money.

8 July 2022 in JMIR Cancer
Verified
Journal Article
Open access
MLMonica Leslie
Monica Leslie
LBLisa Beatty
Lisa Beatty
LHLee Hulbert-Williams
Lee Hulbert-Williams
RPRosina Pendrous
Rosina Pendrous
TCTim Cartwright
Tim Cartwright
NHNicholas J Hulbert-Williams
Nicholas J Hulbert-Williams
Background: Despite high levels of psychological distress experienced by many patients with cancer, previous research has identified several barriers to accessing traditional face-to-face psychological support. Web-based psychosocial interventions have emerged as a promising alternative. Objective: This meta-review aimed to synthesize evidence on recruitment challenges and enablers, factors that promote engagement and adherence to web-based intervention content, and factors that promote the efficacy of web-based psychosocial interventions for patients with cancer and cancer survivors. Methods: We conducted a systematic search of previous reviews that investigated the recruitment, engagement, and efficacy of web-based and app-based psychosocial interventions in adult patients with cancer and cancer survivors. We searched PubMed, CINAHL, PsycINFO, and the Cochrane Library database for relevant literature. The search terms focused on a combination of topics pertaining to neoplasms and telemedicine. Two independent authors conducted abstract screening, full text screening, and data extraction for each identified article. Results: A total of 20 articles met eligibility criteria. There was inconsistency in the reporting of uptake and engagement data; however, anxiety about technology and perceived time burden were identified as 2 key barriers. Web-based psychosocial oncology interventions demonstrated efficacy in reducing depression and stress but reported weak to mixed findings for distress, anxiety, quality of life, and well-being. Although no factors consistently moderated intervention efficacy, preliminary evidence indicated that multicomponent interventions and greater communication with a health care professional were preferred by participants and were associated with superior effects. Conclusions: Several consistently cited barriers to intervention uptake and recruitment have emerged, which we recommend future intervention studies address. Preliminary evidence also supports the superior efficacy of multicomponent interventions and interventions that facilitate communication with a health care professional. However, a greater number of appropriately powered clinical trials, including randomized trials with head-to-head comparisons, are needed to enable more confident conclusions regarding which web-based psychosocial oncology interventions work best and for whom. Trial Registration: PROSPERO CRD42020202633; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=202633

3 July 2018 in European Eating Disorders Review
Verified
Journal Article
Closed access
PDF file
MLMonica Leslie
Monica Leslie
RTRobert Turton
Robert Turton
EBEmilee Burgess
Emilee Burgess
BNBruno Palazzo Nazar
Bruno Palazzo Nazar
Janet TreasureJanet Treasure
Janet Treasure

1 November 2019 in Molecular and Cellular Endocrinology
Verified
Journal Article
Open access
MLMonica Leslie
Monica Leslie
JLJenni Leppanen
Jenni Leppanen
YPYannis Paloyelis
Yannis Paloyelis
Janet TreasureJanet Treasure
Janet Treasure
The current study aimed to test the influence of oxytocin on palatable food intake, 24-h caloric consumption, and stress in women with bulimia nervosa and binge eating disorder. We recruited 25 women with DSM-5 bulimia nervosa or binge eating disorder, and 27 weight-matched comparison women without history of an eating disorder. We employed a double-blind, placebo-controlled crossover design in which each participant attended the lab for two experimental sessions, receiving a divided dose of 64IU intranasal oxytocin in one session and equivalent volume of placebo nasal spray in the opposite session. The order of administration was pseudo-randomised across participants. We hypothesised that a divided dose of 64IU intranasal oxytocin administration would reduce subjective hunger, the immediate consumption of palatable food, 24-h calorie consumption, and the incidence of binge eating when compared to placebo. We also hypothesised that oxytocin administration would be associated with lower levels of stress and salivary cortisol, and that there would be an interaction with participant group such that oxytocin would reduce eating behaviour and stress to a greater degree in women with bulimia nervosa or binge eating disorder, compared to women without history of an eating disorder. We did not find a significant effect of oxytocin on any of the measurements of eating behaviour, subjective stress, or salivary cortisol. We recommend that future studies test the dose-response effect of oxytocin on eating behaviours and stress in human populations with eating disorders to further clarify the moderating factors for oxytocin's effect on eating.